Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy

BACKGROUND: There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in patients with metastatic HR+ HER2− breast cancer previously trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozenblit, Mariya, Mun, Sophia, Soulos, Pamela, Adelson, Kerin, Pusztai, Lajos, Mougalian, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844919/
https://www.ncbi.nlm.nih.gov/pubmed/33514405
http://dx.doi.org/10.1186/s13058-021-01394-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844919/
https://www.ncbi.nlm.nih.gov/pubmed/33514405
http://dx.doi.org/10.1186/s13058-021-01394-y

Ejemplares similares